Hanall Biopharma Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	36,158	24,743	16,386	33,723	16,841	12,794
Short-Term Investments	-	-	-	-	10,000	-
Trading Asset Securities	-	-	8,320	22,775	27,093	67,775
Cash & Short-Term Investments	36,158	24,743	24,706	56,497	53,934	80,570
Cash Growth	166.86%	0.15%	-56.27%	4.75%	-33.06%	-11.18%
Accounts Receivable	15,223	16,869	15,335	15,630	26,689	9,861
Other Receivables	2,402	2,385	4,735	6,894	4,021	5,694
Receivables	17,725	19,354	20,069	22,524	30,709	15,555
Inventory	45,465	38,112	37,702	32,384	25,184	20,408
Prepaid Expenses	79.56	121.05	106.93	93.41	126.5	141.46
Other Current Assets	2,654	2,582	2,769	2,078	1,835	2,141
Total Current Assets	102,082	84,913	85,353	113,577	111,789	118,815
Property, Plant & Equipment	16,424	17,092	18,517	19,434	19,126	19,045
Long-Term Investments	45,040	44,017	44,134	59,626	39,315	23,990
Other Intangible Assets	67,317	4,468	4,537	1,826	2,063	2,219
Long-Term Accounts Receivable	-0	-0	-	-	0	-0
Long-Term Deferred Tax Assets	9,165	9,687	9,469	6,978	8,549	12,220
Long-Term Deferred Charges	-	60,109	47,274	30,783	21,776	16,877
Other Long-Term Assets	3,805	4,939	3,292	7,512	10,833	5,312
Total Assets	243,834	225,224	212,881	239,747	213,451	198,478
Accounts Payable	9,450	5,140	10,679	11,273	4,755	1,759
Accrued Expenses	2,528	2,677	2,297	3,039	2,123	2,147
Short-Term Debt	28,172	15,740	-	-	-	-
Current Portion of Leases	436.69	590.96	748.15	700.22	559.34	423.43
Current Income Taxes Payable	-	-	-	356.7	919.83	94.87
Other Current Liabilities	23,244	20,320	20,996	22,284	20,178	17,695
Total Current Liabilities	63,830	44,468	34,720	37,652	28,535	22,120
Long-Term Debt	15,000	15,000	-	-	-	-
Long-Term Leases	587.4	586.33	699.66	590.31	751.06	911.68
Pension & Post-Retirement Benefits	-	-	403.86	-	-	-
Other Long-Term Liabilities	2,059	3,489	8,705	15,286	15,909	11,954
Total Liabilities	81,477	63,543	44,529	53,529	45,195	34,986
Common Stock	26,120	26,120	26,120	26,120	26,120	26,120
Additional Paid-In Capital	120,707	120,461	116,768	115,040	112,800	112,777
Retained Earnings	21,398	21,123	26,492	31,362	29,409	26,379
Treasury Stock	-14,546	-14,659	-12,587	-13,205	-13,228	-3,254
Comprehensive Income & Other	8,678	8,637	11,558	26,902	13,156	1,469
Shareholders' Equity	162,357	161,681	168,351	186,218	168,256	163,492
Total Liabilities & Equity	243,834	225,224	212,881	239,747	213,451	198,478
Total Debt	44,196	31,917	1,448	1,291	1,310	1,335
Net Cash (Debt)	-8,038	-7,174	23,259	55,207	52,624	79,234
Net Cash Growth	-	-	-57.87%	4.91%	-33.59%	-12.11%
Net Cash Per Share	-155.90	-141.28	458.63	1089.06	1035.58	1547.46
Filing Date Shares Outstanding	55	50.78	50.77	50.69	50.69	51.21
Total Common Shares Outstanding	55	50.78	50.77	50.69	50.69	51.21
Working Capital	38,251	40,445	50,633	75,925	83,254	96,695
Book Value Per Share	2951.90	3183.90	3316.25	3673.44	3319.29	3192.82
Tangible Book Value	95,040	157,214	163,815	184,392	166,193	161,273
Tangible Book Value Per Share	1727.96	3095.93	3226.89	3637.42	3278.59	3149.48
Land	-	1,494	1,494	1,494	1,494	1,494
Buildings	-	17,862	17,467	17,417	17,363	14,968
Machinery	-	13,924	14,021	16,638	16,546	14,294
Construction In Progress	-	-	235.96	514.54	101.28	3,603